Lifecore Biomedical announced that it received a notice on April 13, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Quarterly Report on Form 10-Q for the period ended February 26, 2023 with the Securities and Exchange Commission. The Notice has no immediate effect on the listing or trading of the Company’s securities on the Nasdaq Global Select Market. The Notice states that the Company has 60 calendar days from the date of the Notice, or June 12, 2023, to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the Company’s plan to regain compliance, then Nasdaq may grant the Company up to 180 calendar days from the prescribed due date of the Form 10-Q, or October 10, 2023, to file the Form 10-Q to regain compliance.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LFCR:
- Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
- Lifecore Biomedical Announces Sale of Curation Foods’ O Olive Oil and Vinegar® Business
- Lifecore Biomedical Blasts Up despite Survival Doubts
- Lifecore price target lowered to $8 from $10 at Barrington
- Lifecore downgraded to Equal Weight from Overweight at Stephens
